GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NovelStem International Corp (OTCPK:NSTM) » Definitions » Quality Rank

NovelStem International (NovelStem International) Quality Rank


View and export this data going back to 1995. Start your Free Trial

What is NovelStem International Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

NovelStem International Quality Rank Related Terms

Thank you for viewing the detailed overview of NovelStem International's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

NovelStem International (NovelStem International) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NovelStem International Corp (OTCPK:NSTM) » Definitions » Quality Rank
Comparable Companies
DIGP ISPC NDRA APDN IDTA RNVA SEQL NVTAQ MEDVF IDXG TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN
Traded in Other Exchanges
N/A
Address
2255 Glades Road, Suite 221A, Boca Raton, FL, USA, 33431
Website
https://www.novelstem.com
NovelStem International Corp owns novel stem-cell-based diagnostic technology for predicting patients' resistance to cancer therapies. The technology is also being used for genetic research related to other medical therapies.
Executives
Baker Street Capital Management, Llc 10 percent owner 1875 CENTURY PARK EAST, SUITE 700, LOS ANGELES CA 90067
Vadim Perelman 10 percent owner 1875 CENTURY PARK EAST, SUITE 700, LOS ANGELES CA 90067
Baker Street Capital L.p. 10 percent owner 1875 CENTURY PARK EAST, SUITE 700, LOS ANGELES CA 90067
Stephen Gans director, 10 percent owner 14850 NW 44TH COURT, OPA LOCKA FL 33054
Shannon River Partners Lp 10 percent owner 850 THIRD AVENUE, 13TH FLOOR, NEW YORK NY 10022
Shannon River Fund Management Co Llc 10 percent owner 850 THIRD AVENUE, 13TH FLOOR, NEW YORK NY 10022
Shannon River Partners Ii, Lp 10 percent owner 850 THIRD AVENUE, 13TH FLOOR, NEW YORK NY 10022
Doonbeg Fund Lp 10 percent owner 850 THIRD AVE, 13TH FLOOR, New York ny 10022
Spencer M. Waxman director C/O SHANNON RIVER PARTNERS, 800 THIRD AVENUE 30TH FLOOR, NEW YORK NY 10022
Stanley Morgan 10 percent owner 1585 BROADWAY, NEW YORK NY 10036
Robert D. Epstein director 2255 GLADES ROAD, BOCA RATON FL 33431
Coghill Capital Management Llc 10 percent owner 233 SOUTH WACKER DRIVE, SUITE 8439, CHICAGO IL 60606
Ccm Master Fund Ltd 10 percent owner C/O MORGAN STANLEY FUND SERVICES (CAYMAN, LTD CENTURY YARD CRICKET SQ HUTCHINGS DR, PO BOX 2681 GEORGE TOWN E9 00000
Clint D Coghill 10 percent owner
Scott Gomez officer: Chief Accounting Officer